Corrigendum: Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons

The above article published in Facial Plastic Surgery in Volume 39, Number 6, 719-721, in December 2023 (DOI: 10.1055/a-2148-6321), has been revised to better reflect its focus on the impact GLP-1 receptor agonists have on facial plastic surgeons and their patients. It is not intended to promote the use of GLP-1 receptor agonists for anything other than its FDA-approved use. It is important for facial plastic surgeons to understand the intended use and mechanism of action of these medications and how they may affect the physiology and facial aesthetics of their patients. The article has been updated to reflect the same.

Publikationsverlauf

Artikel online veröffentlicht:
11. April 2024